Compare Stocks → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:AZRXNASDAQ:EYEGNASDAQ:PULMNASDAQ:SBPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.19$1.79$1.08▼$5.50$9.43M0.9612,181 shs3,902 shsAZRXAzurRx BioPharma$3.02-3.2%$4.04$3.36▼$26.30$28.17M1.51628,703 shs48,444 shsEYEGAB Corporate Bond ETF$34.62-0.3%$1.90$1.44▼$8.18$24.24M0.13935,975 shs300 shsPULMPulmatrix$2.08+3.0%$1.86$1.55▼$3.14$7.59M0.9217,460 shs2,103 shsSBPHSpring Bank Pharmaceuticals$8.00$0.80▼$4.80$122.94M1.07177,606 shsN/ABeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%-1.65%-36.02%-55.01%-68.68%AZRXAzurRx BioPharma-3.21%+6.34%-23.93%-38.99%+5.96%EYEGAB Corporate Bond ETF-0.28%-0.09%-2.67%-2.73%+1,675.58%PULMPulmatrix-0.48%+6.67%+23.03%+15.56%-24.09%SBPHSpring Bank Pharmaceuticals0.00%0.00%0.00%0.00%0.00%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/APULMPulmatrix1.4483 of 5 stars3.53.00.00.01.40.00.6SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/APULMPulmatrix3.00Buy$10.00380.77% UpsideSBPHSpring Bank PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AEYEGAB Corporate Bond ETF$10K2,423.67N/AN/A$1.26 per share27.48PULMPulmatrix$7.30M1.04N/AN/A$4.93 per share0.42SBPHSpring Bank PharmaceuticalsN/AN/AN/AN/A$2.16 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)AZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AEYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/APULMPulmatrix-$14.12M-$3.86N/A∞N/A-193.49%-63.94%-40.88%5/10/2024 (Estimated)SBPHSpring Bank Pharmaceuticals-$24.10M-$1.47N/AN/AN/AN/A-89.89%-52.89%N/ALatest PULM, AZRX, SBPH, EYEG, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023PULMPulmatrixN/A-$0.57-$0.57-$0.57N/A$2.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/APULMPulmatrixN/AN/AN/AN/AN/ASBPHSpring Bank PharmaceuticalsN/AN/AN/AN/AN/ALatest PULM, AZRX, SBPH, EYEG, and AKTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/28/2024EYEGAB Corporate Bond ETFMonthly$0.15724/1/20244/2/20244/5/20242/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.950.95AZRXAzurRx BioPharmaN/A1.331.33EYEGAB Corporate Bond ETF0.013.073.07PULMPulmatrixN/A5.335.33SBPHSpring Bank PharmaceuticalsN/A5.115.11OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%AZRXAzurRx BioPharma6.27%EYEGAB Corporate Bond ETF64.16%PULMPulmatrix11.84%SBPHSpring Bank Pharmaceuticals17.17%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%AZRXAzurRx BioPharma7.30%EYEGAB Corporate Bond ETF58.20%PULMPulmatrix3.61%SBPHSpring Bank Pharmaceuticals12.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics157.92 million3.03 millionNot OptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableEYEGAB Corporate Bond ETF14700,0005.28 millionNot OptionablePULMPulmatrix223.65 million3.52 millionNot OptionableSBPHSpring Bank Pharmaceuticals3017.27 millionN/ANot OptionablePULM, AZRX, SBPH, EYEG, and AKTX HeadlinesSourceHeadlineWhen will interest rates go down?thetimes.co.uk - January 31 at 12:12 PMBank of Canada expected to 'cautiously' start cutting rates in spring: Deloitte Canadaca.finance.yahoo.com - January 6 at 2:22 PMMan stabbed during street fight in Spring Bank Westhulldailymail.co.uk - September 29 at 8:36 AMWhen is the next Bank Holiday and how many are left in 2023?dailyecho.co.uk - August 13 at 4:35 AMSpring Bank fight involved two feuding families, police believehulldailymail.co.uk - August 8 at 3:14 PMCalls for more police patrols on Spring Bank after fight leaves three in hospitalhulldailymail.co.uk - August 8 at 10:14 AMSpring Bank fight: Six men and a woman held over shocking street violencehulldailymail.co.uk - August 7 at 5:57 AMThe mysterious structure on Spring Bank created to shoot out a beam of lighthulldailymail.co.uk - August 5 at 10:31 AMSyria’s Economic Outlook- Spring 2016worldbank.org - July 23 at 2:47 PMHoliday spending by bank’s customers jumped by 40% annually this springindependent.co.uk - July 17 at 9:22 AMHull's Spring Bank set for major regeneration as plans announced to make it more 'attractive'hulldailymail.co.uk - June 30 at 12:00 PMSpring 2023 Layoff Tracker: Grubhub Cuts 400 Staffforbes.com - June 14 at 8:29 PMRibchester to host 36th annual Spring Bank marketlancashiretelegraph.co.uk - June 7 at 11:53 PMThree big changes for DWP benefit payments including Spring Bank Holidaybirminghammail.co.uk - June 2 at 7:19 PMWhat shops are open this spring bank holiday Monday 2023?metro.co.uk - May 30 at 9:46 AMDWP benefit payment date changes over Spring bank holiday weekendmetro.co.uk - May 28 at 9:06 AMWhen is the the next UK Bank Holiday and how many are left in 2023?uk.news.yahoo.com - May 20 at 4:36 PMWorld Bank, IMF Spring Meetings 2023: What did FMs, central bank governors discuss?moneycontrol.com - April 23 at 3:11 PMThe three bank holidays in May as King's Coronation approachesmanchestereveningnews.co.uk - April 23 at 3:11 PMKing's Coronation bank holiday weekend could get workers 10 days off with just 4 days leavemanchestereveningnews.co.uk - April 21 at 11:06 PMIMF and World Bank Spring Meetings, NRA-ILA Leadership Forum, UN in Libya, and Morecfr.org - April 18 at 9:11 AMWorld Bank, IMF spring meetings get underway in complex economic environmentchannelnewsasia.com - April 18 at 9:11 AMSpring sales 2023: Best deals to shop this Easter bank holidayaol.co.uk - April 10 at 10:13 AMWhen are the bank holidays around the King's coronation?manchestereveningnews.co.uk - April 8 at 10:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.AzurRx BioPharmaNASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.PulmatrixNASDAQ:PULMPulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Spring Bank PharmaceuticalsNASDAQ:SBPHSpring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.